{ "instance": { "tmb-20210630x10q.htm": { "axisCustom": 0, "axisStandard": 12, "contextCount": 224, "dts": { "calculationLink": { "local": [ "tmb-20210630_cal.xml" ] }, "definitionLink": { "local": [ "tmb-20210630_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tmb-20210630x10q.htm" ] }, "labelLink": { "local": [ "tmb-20210630_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "tmb-20210630_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml" ] }, "schema": { "local": [ "tmb-20210630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 309, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 8, "http://xbrl.sec.gov/dei/2020-01-31": 5, "total": 13 }, "keyCustom": 48, "keyStandard": 219, "memberCustom": 19, "memberStandard": 16, "nsprefix": "mbio", "nsuri": "http://www.mustangbio.com/20210630", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Related Party Agreements", "role": "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreements", "shortName": "Related Party Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Property and Equipment", "role": "http://www.mustangbio.com/role/DisclosurePropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Accounts Payable and Accrued Expenses", "role": "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpenses", "shortName": "Accounts Payable and Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Stockholders' Equity", "role": "http://www.mustangbio.com/role/DisclosureStockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Net Loss per Share", "role": "http://www.mustangbio.com/role/DisclosureNetLossPerShare", "shortName": "Net Loss per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20202 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30203 - Disclosure - Significant Accounting Policies (Tables)", "role": "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesTables", "shortName": "Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_vmWlbm9GXUKFV_GHfXBOdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (Tables)", "role": "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsTables", "shortName": "License, Clinical Trial and Sponsored Research Agreements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_vmWlbm9GXUKFV_GHfXBOdg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Property and Equipment (Tables)", "role": "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - Accounts Payable and Accrued Expenses (Tables)", "role": "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesTables", "shortName": "Accounts Payable and Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_4NmZGkJt_U2fLEIXqjSDNA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_GqpR2iU5fUOluw3mIUd2iQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - CONDENSED BALANCE SHEETS", "role": "http://www.mustangbio.com/role/StatementCondensedBalanceSheets", "shortName": "CONDENSED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_4NmZGkJt_U2fLEIXqjSDNA", "decimals": "-3", "lang": null, "name": "us-gaap:OtherReceivables", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GqpR2iU5fUOluw3mIUd2iQ", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30703 - Disclosure - Stockholders' Equity (Tables)", "role": "http://www.mustangbio.com/role/DisclosureStockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30803 - Disclosure - Net Loss per Share (Tables)", "role": "http://www.mustangbio.com/role/DisclosureNetLossPerShareTables", "shortName": "Net Loss per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_4NmZGkJt_U2fLEIXqjSDNA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "Unit_Standard_USD_GqpR2iU5fUOluw3mIUd2iQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - Organization, Description of Business and Liquidity and Capital Resources (Details)", "role": "http://www.mustangbio.com/role/DisclosureOrganizationDescriptionOfBusinessAndLiquidityAndCapitalResourcesDetails", "shortName": "Organization, Description of Business and Liquidity and Capital Resources (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R23": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_4NmZGkJt_U2fLEIXqjSDNA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_GqpR2iU5fUOluw3mIUd2iQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - Significant Accounting Policies (Cash, Cash Equivalents, and Restricted Cash) (Details)", "role": "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails", "shortName": "Significant Accounting Policies (Cash, Cash Equivalents, and Restricted Cash) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "As_Of_6_30_2020_Sj5O8L1VA0q02t_-aDavfw", "decimals": "-3", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GqpR2iU5fUOluw3mIUd2iQ", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_qYypopiC0UunbqD7xAPPXQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "reportCount": 1, "unitRef": "Unit_Standard_USD_GqpR2iU5fUOluw3mIUd2iQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (City of Hope - Licenses) (Narrative) (Details)", "role": "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails", "shortName": "License, Clinical Trial and Sponsored Research Agreements (City of Hope - Licenses) (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_4_1_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_Io964lq3V0aVP0rBatDR4w", "decimals": "0", "lang": null, "name": "mbio:AnnualMaintenanceFeePayable", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GqpR2iU5fUOluw3mIUd2iQ", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_qYypopiC0UunbqD7xAPPXQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "reportCount": 1, "unitRef": "Unit_Standard_USD_GqpR2iU5fUOluw3mIUd2iQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40302 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (City of Hope - Sponsored Research and Clinical Trial Agreements) (Narrative) (Details)", "role": "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "shortName": "License, Clinical Trial and Sponsored Research Agreements (City of Hope - Sponsored Research and Clinical Trial Agreements) (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_3_1_2015_To_3_31_2015_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_fZnrDFAWLkGz3RRjP885IQ", "decimals": "-6", "lang": null, "name": "mbio:MilestonesPayableUnderArrangement", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GqpR2iU5fUOluw3mIUd2iQ", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_qYypopiC0UunbqD7xAPPXQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "reportCount": 1, "unitRef": "Unit_Standard_USD_GqpR2iU5fUOluw3mIUd2iQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40303 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (Other - Sponsored Research and Clinical Trial Agreements) (Narrative) (Details)", "role": "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "shortName": "License, Clinical Trial and Sponsored Research Agreements (Other - Sponsored Research and Clinical Trial Agreements) (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_6_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_oh7ApSlfsEif9Z3fWWqx_w", "decimals": "-5", "lang": null, "name": "mbio:MilestonesPayableUnderArrangement", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GqpR2iU5fUOluw3mIUd2iQ", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_qYypopiC0UunbqD7xAPPXQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "reportCount": 1, "unitRef": "Unit_Standard_USD_GqpR2iU5fUOluw3mIUd2iQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40304 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (License Agreements) (Details)", "role": "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails", "shortName": "License, Clinical Trial and Sponsored Research Agreements (License Agreements) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R28": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_qYypopiC0UunbqD7xAPPXQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "reportCount": 1, "unitRef": "Unit_Standard_USD_GqpR2iU5fUOluw3mIUd2iQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40305 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (Sponsored Research and Clinical Trial Agreements) (Details)", "role": "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails", "shortName": "License, Clinical Trial and Sponsored Research Agreements (Sponsored Research and Clinical Trial Agreements) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_V1z59kmYSUSHumqf0ASm7A", "decimals": "-3", "lang": null, "name": "mbio:ResearchAndDevelopmentIncomeExpensesSponsoredResearchAndClinicalTrialAgreements", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GqpR2iU5fUOluw3mIUd2iQ", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unitRef": "Unit_Standard_USD_GqpR2iU5fUOluw3mIUd2iQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Related Party Agreements (Narrative) (Details)", "role": "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails", "shortName": "Related Party Agreements (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "mbio:PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses", "mbio:PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses", "mbio:PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_GhieQxLGJESIe7jGjCj_ig", "decimals": "2", "lang": null, "name": "mbio:PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_1DjiFE2M9EKMZNfKLqgozQ", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_4NmZGkJt_U2fLEIXqjSDNA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_AoMFsvegY0asOS2GEqCRhg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)", "role": "http://www.mustangbio.com/role/StatementCondensedBalanceSheetsParenthetical", "shortName": "CONDENSED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_4NmZGkJt_U2fLEIXqjSDNA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_AoMFsvegY0asOS2GEqCRhg", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_qYypopiC0UunbqD7xAPPXQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GqpR2iU5fUOluw3mIUd2iQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Property and Equipment (Narrative) (Details)", "role": "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentNarrativeDetails", "shortName": "Property and Equipment (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_qYypopiC0UunbqD7xAPPXQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GqpR2iU5fUOluw3mIUd2iQ", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_4NmZGkJt_U2fLEIXqjSDNA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GqpR2iU5fUOluw3mIUd2iQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40502 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)", "role": "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails", "shortName": "Property and Equipment (Schedule of Property and Equipment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_4NmZGkJt_U2fLEIXqjSDNA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GqpR2iU5fUOluw3mIUd2iQ", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_4NmZGkJt_U2fLEIXqjSDNA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GqpR2iU5fUOluw3mIUd2iQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Accounts Payable and Accrued Expenses (Schedule of Accounts Payable and Accrued Expenses) (Details)", "role": "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails", "shortName": "Accounts Payable and Accrued Expenses (Schedule of Accounts Payable and Accrued Expenses) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_4NmZGkJt_U2fLEIXqjSDNA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GqpR2iU5fUOluw3mIUd2iQ", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_4NmZGkJt_U2fLEIXqjSDNA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Unit_Standard_shares_ZMy7XIL63UqYh7HJBDNMHA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Stockholders' Equity (Common Stock and Equity Offerings) (Narrative) (Details)", "role": "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails", "shortName": "Stockholders' Equity (Common Stock and Equity Offerings) (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_qYypopiC0UunbqD7xAPPXQ", "decimals": "0", "lang": null, "name": "mbio:EmployeeStockPurchasePlanShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GqpR2iU5fUOluw3mIUd2iQ", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "As_Of_12_31_2019_rNufU0cKgkyBCOlQp2uyCg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_ZMy7XIL63UqYh7HJBDNMHA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40702 - Disclosure - Stockholders' Equity (Equity Incentive Plans) (Narrative) (Details)", "role": "http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlansNarrativeDetails", "shortName": "Stockholders' Equity (Equity Incentive Plans) (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "As_Of_12_31_2019_rNufU0cKgkyBCOlQp2uyCg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_ZMy7XIL63UqYh7HJBDNMHA", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40703 - Disclosure - Stockholders' Equity (Stock Option Activities) (Details)", "role": "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails", "shortName": "Stockholders' Equity (Stock Option Activities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_asOBQUPgoUCK0ExgxI171Q", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_ZMy7XIL63UqYh7HJBDNMHA", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40704 - Disclosure - Stockholders' Equity (Restricted Stock/Units Awards) (Details)", "role": "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsAwardsDetails", "shortName": "Stockholders' Equity (Restricted Stock/Units Awards) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_yaySxfowcU6-QJMyOtIeeQ", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_ZMy7XIL63UqYh7HJBDNMHA", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_qYypopiC0UunbqD7xAPPXQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GqpR2iU5fUOluw3mIUd2iQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40705 - Disclosure - Stockholders' Equity (Stock-based Compensation Expense) (Details)", "role": "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails", "shortName": "Stockholders' Equity (Stock-based Compensation Expense) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_qYypopiC0UunbqD7xAPPXQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GqpR2iU5fUOluw3mIUd2iQ", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "mbio:SummaryOfWarrantActivitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_hGHUUsJ5xUmBt7CjNEjuyQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Unit_Standard_shares_ZMy7XIL63UqYh7HJBDNMHA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40706 - Disclosure - Stockholders' Equity (Warrants Activity) (Details)", "role": "http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails", "shortName": "Stockholders' Equity (Warrants Activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "mbio:SummaryOfWarrantActivitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_L1LRGlD_vkGeYV8d5a-1mg", "decimals": "INF", "lang": null, "name": "mbio:ClassOfWarrantOrRightWarrantsExercisedDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_ZMy7XIL63UqYh7HJBDNMHA", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_ZMy7XIL63UqYh7HJBDNMHA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Net Loss per Share (Potentially Dilutive Securities) (Details)", "role": "http://www.mustangbio.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesDetails", "shortName": "Net Loss per Share (Potentially Dilutive Securities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_ZMy7XIL63UqYh7HJBDNMHA", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_qYypopiC0UunbqD7xAPPXQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "reportCount": 1, "unitRef": "Unit_Standard_USD_GqpR2iU5fUOluw3mIUd2iQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - CONDENSED STATEMENTS OF OPERATIONS", "role": "http://www.mustangbio.com/role/StatementCondensedStatementsOfOperations", "shortName": "CONDENSED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_qYypopiC0UunbqD7xAPPXQ", "decimals": "-3", "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GqpR2iU5fUOluw3mIUd2iQ", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_m5yHouIn-EGlItBLh8oBKA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GqpR2iU5fUOluw3mIUd2iQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY", "role": "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity", "shortName": "CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_m5yHouIn-EGlItBLh8oBKA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GqpR2iU5fUOluw3mIUd2iQ", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_GqpR2iU5fUOluw3mIUd2iQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - CONDENSED STATEMENTS OF CASH FLOWS", "role": "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows", "shortName": "CONDENSED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": "-3", "lang": null, "name": "mbio:IssuanceOfCommonSharesEquityFeeOnAtMarketOffering", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_GqpR2iU5fUOluw3mIUd2iQ", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Organization, Description of Business and Liquidity and Capital Resources", "role": "http://www.mustangbio.com/role/DisclosureOrganizationDescriptionOfBusinessAndLiquidityAndCapitalResources", "shortName": "Organization, Description of Business and Liquidity and Capital Resources", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Significant Accounting Policies", "role": "http://www.mustangbio.com/role/DisclosureSignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - License, Clinical Trial and Sponsored Research Agreements", "role": "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreements", "shortName": "License, Clinical Trial and Sponsored Research Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "tmb-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_1IjrGXqs2E-XYTcGkw_s3g", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 40, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "mbio_AccruedCompensationCurrent": { "auth_ref": [], "calculation": { "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for accrued compensation.", "label": "Accrued Compensation Current", "terseLabel": "Accrued compensation" } } }, "localname": "AccruedCompensationCurrent", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "mbio_AdditionalMilestonesPayableUnderArrangement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of additional milestones payable under the arrangement.", "label": "Additional Milestones Payable Under Arrangement", "terseLabel": "Additional milestone payments" } } }, "localname": "AdditionalMilestonesPayableUnderArrangement", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mbio_AnnualMaintenanceFeePayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of annual maintenance fee payable under the arrangement.", "label": "Annual Maintenance Fee Payable", "terseLabel": "Annual maintenance fee payable" } } }, "localname": "AnnualMaintenanceFeePayable", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mbio_AtMarketOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to issuances of stock offered on an At The Market basis.", "label": "At Market Offering [Member]", "terseLabel": "At the Market Offering [Member]" } } }, "localname": "AtMarketOfferingMember", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mbio_Cd123ProductOrProcessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to CD123, a pharmaceutical product or process.", "label": "Cd123 Product Or Process [Member]", "terseLabel": "CD123 Product or Process [Member]" } } }, "localname": "Cd123ProductOrProcessMember", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails" ], "xbrltype": "domainItemType" }, "mbio_Cd20TechnologyProductOrProcessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to CD20 Technology License.", "label": "Cd20 Technology Product Or Process [Member]", "terseLabel": "CD20 Product or Process [Member]" } } }, "localname": "Cd20TechnologyProductOrProcessMember", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails" ], "xbrltype": "domainItemType" }, "mbio_CityOfHopeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to City of hope, a pharmaceutical product or process.", "label": "City Of Hope [Member]", "terseLabel": "City of Hope [Member]" } } }, "localname": "CityOfHopeMember", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails" ], "xbrltype": "domainItemType" }, "mbio_CityOfHopeNationalMedicalCenterCohMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to City Of Hope National Medical Center (\"COH\"), a counterparty in agreement(s) with the entity.", "label": "City Of Hope National Medical Center Coh [Member]", "terseLabel": "City of Hope National Medical Center (\"COH\") [Member]" } } }, "localname": "CityOfHopeNationalMedicalCenterCohMember", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails" ], "xbrltype": "domainItemType" }, "mbio_ClassOfWarrantOrRightWarrantsExercisedDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants or rights exercised during the period.", "label": "Class Of Warrant Or Right, Warrants Exercised During The Period", "negatedLabel": "Warrants exercised" } } }, "localname": "ClassOfWarrantOrRightWarrantsExercisedDuringPeriod", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "mbio_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisedDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of warrants that were exercised during the period.", "label": "Class Of Warrant Or Right Weighted Average Exercise Price Exercised During The Period", "terseLabel": "Warrant exercise price, exercised during the period (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceExercisedDuringPeriod", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average remaining contractual life for warrants outstanding.", "label": "Class Of Warrant Or Right Weighted Average Remaining Contractual Life", "terseLabel": "Warrants outstanding, remaining contractual life" } } }, "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualLife", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails" ], "xbrltype": "durationItemType" }, "mbio_CommissionRatePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of commission rate on gross sale of common stock.", "label": "Commission Rate Percentage", "terseLabel": "Agent commission (as a percent)" } } }, "localname": "CommissionRatePercentage", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails" ], "xbrltype": "percentItemType" }, "mbio_CommonStockIssuableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Issuable [Member]", "terseLabel": "Common Stock Issuable [Member]" } } }, "localname": "CommonStockIssuableMember", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "mbio_CommonStockSharesAvailableForFutureIssuanceValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common Stock Shares Available For Future Issuance Value", "label": "Common Stock Shares Available For Future Issuance Value", "terseLabel": "Common stock shares available for future issuance" } } }, "localname": "CommonStockSharesAvailableForFutureIssuanceValue", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mbio_CommonUnspecifiedClassMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Unspecified Class [Member]", "terseLabel": "Common Shares [Member]" } } }, "localname": "CommonUnspecifiedClassMember", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation", "http://www.mustangbio.com/role/StatementCondensedBalanceSheets", "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "mbio_ConstructionInProcessNet": { "auth_ref": [], "calculation": { "http://www.mustangbio.com/role/StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of assets under construction.", "label": "Construction In Process Net", "verboseLabel": "Fixed assets - construction in process" } } }, "localname": "ConstructionInProcessNet", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "mbio_ContributionTowardPatientCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of contribution to be paid toward patient costs.", "label": "Contribution Toward Patient Costs", "terseLabel": "Contribution toward patient costs" } } }, "localname": "ContributionTowardPatientCosts", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mbio_Cs1ProductOrProcessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to CS1, a pharmaceutical product or process.", "label": "Cs1 Product Or Process [Member]", "terseLabel": "CS1 Product or Process [Member]" } } }, "localname": "Cs1ProductOrProcessMember", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails" ], "xbrltype": "domainItemType" }, "mbio_DilutedOutstandingEquityPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of diluted outstanding equity paid as equity fee or used to calculate stock issuance to maintain parity.", "label": "Diluted Outstanding Equity, Percentage", "terseLabel": "Percentage of fully diluted equity" } } }, "localname": "DilutedOutstandingEquityPercentage", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails" ], "xbrltype": "percentItemType" }, "mbio_EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee stock purchase plan, predetermined offering period, lower fair market value percentage.", "label": "Employee Stock Purchase Plan, Predetermined Offering Period, Lower Fair Market Value Percentage", "terseLabel": "Predetermined offering period, lower fair market value percentage" } } }, "localname": "EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlansNarrativeDetails" ], "xbrltype": "percentItemType" }, "mbio_EmployeeStockPurchasePlanShareBasedCompensationExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of share-based compensation expense recognized under Employee Stock Purchase Plan.", "label": "Employee Stock Purchase Plan, Share-based Compensation Expense", "terseLabel": "Share-based compensation expense under ESPP" } } }, "localname": "EmployeeStockPurchasePlanShareBasedCompensationExpense", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mbio_FortressBiotechIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fortress Biotech Inc [Member]", "terseLabel": "Fortress Biotech, Inc [Member]" } } }, "localname": "FortressBiotechIncMember", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mbio_FredHutchinsonCancerResearchCenterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Fred Hutchinson Cancer Research Center, a counterparty in agreement(s) with the entity.", "label": "Fred Hutchinson Cancer Research Center [Member]", "terseLabel": "Fred Hutchinson Cancer Research Center [Member]" } } }, "localname": "FredHutchinsonCancerResearchCenterMember", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails" ], "xbrltype": "domainItemType" }, "mbio_Her2ProductOrProcessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to HER2, a pharmaceutical product or process.", "label": "Her2 Product Or Process [Member]", "terseLabel": "HER2 Product or Process [Member]" } } }, "localname": "Her2ProductOrProcessMember", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails" ], "xbrltype": "domainItemType" }, "mbio_Il13r2ProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Il13r2, a pharmaceutical product.", "label": "Il13r2 Product [Member]", "terseLabel": "IL13Ra2 Product [Member]" } } }, "localname": "Il13r2ProductMember", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails" ], "xbrltype": "domainItemType" }, "mbio_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties": { "auth_ref": [], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid excluding those attributable to related parties.", "label": "Increase (Decrease) In Accounts Payable And Accrued Expenses Excluding Amounts Due To Related Parties", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mbio_IncreaseDecreaseInLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of Increase Decrease In Lease Liabilities.", "label": "Increase Decrease In Lease Liabilities", "negatedLabel": "Lease liabilities" } } }, "localname": "IncreaseDecreaseInLeaseLiabilities", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mbio_IssuanceOfCommonSharesEquityFeeOnAtMarketOffering": { "auth_ref": [], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "It Represents issuance of common stock for equity fee at market offering.", "label": "Issuance Of Common Shares Equity Fee On At Market Offering", "verboseLabel": "Issuance of common shares - Equity fee on At-the-Market Offering to Fortress Biotech" } } }, "localname": "IssuanceOfCommonSharesEquityFeeOnAtMarketOffering", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mbio_IssuanceOfCommonSharesEquityFeeOnPublicOffering": { "auth_ref": [], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "It represents issuance of common stock on public offering.", "label": "Issuance Of Common Shares Equity Fee On Public Offering", "verboseLabel": "Issuance of common shares - Equity fee on Public Offering to Fortress Biotech" } } }, "localname": "IssuanceOfCommonSharesEquityFeeOnPublicOffering", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mbio_LeaseLiabilitiesArisingFromObtainingRightOfUseAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease liabilities arising from obtaining right-of-use assets", "label": "Lease liabilities arising from obtaining right-of-use assets", "terseLabel": "Lease liabilities arising from obtaining right-of-use assets" } } }, "localname": "LeaseLiabilitiesArisingFromObtainingRightOfUseAssets", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mbio_LicenseAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to collaborative agreements involving pharmaceutical products or processes.", "label": "License Agreements [Member]", "terseLabel": "License Agreements [Member]" } } }, "localname": "LicenseAgreementsMember", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsTables" ], "xbrltype": "domainItemType" }, "mbio_MayoClinicMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mayo Clinic [Member]", "label": "Mayo Clinic [Member]", "terseLabel": "Mayo Clinic [Member]" } } }, "localname": "MayoClinicMember", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails" ], "xbrltype": "domainItemType" }, "mbio_MilestonesPayableUnderArrangement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of milestones payable under the arrangement.", "label": "Milestones Payable Under The Arrangement", "terseLabel": "Milestones payable" } } }, "localname": "MilestonesPayableUnderArrangement", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mbio_NumberOfMilestonesMeasured": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of milestones measured under the arrangement.", "label": "Number Of Milestones Measured", "terseLabel": "Number of milestones" } } }, "localname": "NumberOfMilestonesMeasured", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails" ], "xbrltype": "integerItemType" }, "mbio_OfferingCostsForIssuanceOfCommonSharesAtMarketOffering": { "auth_ref": [], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Offering costs for the issuance of common shares - At-the-Market Offering.", "label": "Offering Costs For the Issuance of Common Shares - At-the-Market Offering", "negatedLabel": "Offering costs for the issuance of common shares - At-the-Market Offering" } } }, "localname": "OfferingCostsForIssuanceOfCommonSharesAtMarketOffering", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mbio_OfferingCostsForIssuanceOfCommonSharesPublicOfferingInAccountsPayableAndAccruedExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Offering costs for the issuance of common shares - Public Offering, in accounts payable and accrued expenses.", "label": "Offering costs for the issuance of common shares - Public Offering, in accounts payable and accrued expenses", "terseLabel": "Offering costs for the issuance of common shares - Public Offering, in accounts payable and accrued expenses" } } }, "localname": "OfferingCostsForIssuanceOfCommonSharesPublicOfferingInAccountsPayableAndAccruedExpenses", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mbio_OperatingLeaseRightOfUseAssetsAmortization": { "auth_ref": [], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Operating Lease Right Of Use Assets Amortization.", "label": "Operating Lease Right Of Use Assets Amortization", "verboseLabel": "Amortization of operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAssetsAmortization", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mbio_PaymentOfUpfrontFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payment of Upfront Fees", "label": "Payment Of Upfront Fees", "terseLabel": "Upfront fees paid" } } }, "localname": "PaymentOfUpfrontFees", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mbio_PercentageOfAnnualFeesExpenseRelatedToManagementServicesAgreementRecordedInGeneralAndAdministrativeExpenses": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of annual fees expense related to Management Services Agreement recorded in general and administrative expenses", "label": "Percentage of annual fees expense related to Management Services Agreement recorded in general and administrative expenses", "terseLabel": "Percentage of annual fees expense related to Management Services Agreement recorded in general and administrative expenses" } } }, "localname": "PercentageOfAnnualFeesExpenseRelatedToManagementServicesAgreementRecordedInGeneralAndAdministrativeExpenses", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails" ], "xbrltype": "percentItemType" }, "mbio_PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of annual fees expense related to Management Services Agreement recorded in research and development expenses", "label": "Percentage of Annual Fees Expenses Related to Management Services Agreement recorded in research and development expenses", "terseLabel": "Percentage of annual fees expense related to Management Services Agreement recorded in research and development expenses" } } }, "localname": "PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails" ], "xbrltype": "percentItemType" }, "mbio_ProceedsFromEmployeeStockPurchasePlan": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "It represents the amount of proceeds from employee stock purchase plan.", "label": "Proceeds From Employee Stock Purchase Plan", "terseLabel": "Proceeds from employee stock purchase plan" } } }, "localname": "ProceedsFromEmployeeStockPurchasePlan", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mbio_ProceedsFromIssuanceOfCommonSharesAtMarketOffering": { "auth_ref": [], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common shares - At-the-Market Offering.", "label": "Proceeds From Issuance of Common Shares, At-the-Market Offering", "terseLabel": "Proceeds from issuance of common shares - At-the-Market Offering" } } }, "localname": "ProceedsFromIssuanceOfCommonSharesAtMarketOffering", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mbio_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Issuance Of Common Stock, net of offering costs.", "label": "Proceeds From Issuance Of Common Stock, net of offering costs", "terseLabel": "Proceeds from issuance of Common Stock, net of offering costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mbio_PropertyPlantAndEquipmentExcludingAssetsUnderConstruction": { "auth_ref": [], "calculation": { "http://www.mustangbio.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale but excluding construction in process assets.", "label": "Property, Plant And Equipment Excluding Assets Under Construction", "verboseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentExcludingAssetsUnderConstruction", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "mbio_PscaProductOrProcessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to PSCA, a pharmaceutical product or process.", "label": "Psca Product Or Process [Member]", "terseLabel": "PSCA Product or Process [Member]" } } }, "localname": "PscaProductOrProcessMember", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails" ], "xbrltype": "domainItemType" }, "mbio_RegistrationStatementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Registration Statements [Member]", "label": "Registration Statements [Member]", "terseLabel": "Registration Statements [Member]" } } }, "localname": "RegistrationStatementsMember", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mbio_ResearchAndDevelopmentCurrent": { "auth_ref": [], "calculation": { "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for research and development.", "label": "Research and Development Current", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentCurrent", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "mbio_ResearchAndDevelopmentIncomeExpensesSponsoredResearchAndClinicalTrialAgreements": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research and Development Expenses - Sponsored Research and Clinical Trial Agreements", "label": "Research and Development Expenses - Sponsored Research and Clinical Trial Agreements", "negatedLabel": "Research and Development (Income) Expenses" } } }, "localname": "ResearchAndDevelopmentIncomeExpensesSponsoredResearchAndClinicalTrialAgreements", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "mbio_ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense": { "auth_ref": [], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "R&D include in Accounts payable and accrued expense.", "label": "Research And Development License In Accounts Payable And Accrued Expense", "verboseLabel": "Research and development - licenses acquired" } } }, "localname": "ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mbio_ResearchAndDevelopmentLicensesExpenditureIncurredButNotYetPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for research and development licenses expenditures that have occurred.", "label": "Research And Development Licenses Expenditure Incurred But Not Yet Paid", "terseLabel": "Research and development licenses included in accounts payable and accrued expenses" } } }, "localname": "ResearchAndDevelopmentLicensesExpenditureIncurredButNotYetPaid", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mbio_ResearchArrangementContributionPerPatient": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of contribution to be paid per patient under the arrangement.", "label": "Research Arrangement, Contribution Per Patient", "terseLabel": "Contribution per patient" } } }, "localname": "ResearchArrangementContributionPerPatient", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mbio_ResearchArrangementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The term of the research arrangement.", "label": "Research Arrangement Term", "terseLabel": "Agreement term" } } }, "localname": "ResearchArrangementTerm", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails" ], "xbrltype": "durationItemType" }, "mbio_ResearchFundingPayableNumberOfInstallments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of installments in which the research funding is to be paid.", "label": "Research Funding Payable, Number Of Installments", "terseLabel": "Number of installments" } } }, "localname": "ResearchFundingPayableNumberOfInstallments", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails" ], "xbrltype": "integerItemType" }, "mbio_SaleOfStockAggregateOfferingPricePermittedByAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sale of Stock aggregate offering price permitted by agreement.", "label": "Sale of Stock aggregate offering price permitted by agreement", "terseLabel": "Sale of Stock aggregate offering price permitted by agreement" } } }, "localname": "SaleOfStockAggregateOfferingPricePermittedByAgreement", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mbio_ShareIssuedDuringPeriodSharesOnExerciseOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued on exercise of warrants.", "label": "Share Issued During Period, Shares, On Exercise Of Warrants", "terseLabel": "Exercise of warrants (in shares)" } } }, "localname": "ShareIssuedDuringPeriodSharesOnExerciseOfWarrants", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "mbio_ShareIssuedDuringPeriodValueOnExerciseOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of shares issued on exercise of warrants.", "label": "Share Issued During Period, Value, On Exercise Of Warrants", "terseLabel": "Exercise of warrants" } } }, "localname": "ShareIssuedDuringPeriodValueOnExerciseOfWarrants", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "mbio_SignificantAccountingPoliciesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of material changes to the company's significant accounting policies previously disclosed.", "label": "Significant Accounting Policies [Policy Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesPolicyTextBlock", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "mbio_SpacerTechnologyProductOrProcessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to spacer technology, a pharmaceutical product or process.", "label": "Spacer Technology Product Or Process [Member]", "terseLabel": "Spacer Product or Process [Member]" } } }, "localname": "SpacerTechnologyProductOrProcessMember", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "mbio_SponsoredResearchAndClinicalTrialAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to collaborative agreements involving sponsored research and clinical trials of pharmaceutical products or processes.", "label": "Sponsored Research And Clinical Trial Agreements [Member]", "terseLabel": "Sponsored Research and Clinical Trial Agreements [Member]" } } }, "localname": "SponsoredResearchAndClinicalTrialAgreementsMember", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsTables" ], "xbrltype": "domainItemType" }, "mbio_St.JudeChildrensResearchHospitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "St. Jude Children's Research Hospital [Member]", "label": "St. Jude Childrens Research Hospital [Member]", "terseLabel": "St. Jude Children's Research Hospital [Member]" } } }, "localname": "St.JudeChildrensResearchHospitalMember", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails" ], "xbrltype": "domainItemType" }, "mbio_StJudeXscidMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to St Jude - XSCID, a pharmaceutical product or process.", "label": "St Jude Xscid [Member]", "terseLabel": "ST. Jude - XSCID [Member]" } } }, "localname": "StJudeXscidMember", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails" ], "xbrltype": "domainItemType" }, "mbio_StockIssuedDuringPeriodSharesAtMarketOffering": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued at the market offering", "label": "Stock Issued During Period Shares , At The Market Offering", "verboseLabel": "Issuance of common shares, net of offering costs - At-the-Market Offering (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAtMarketOffering", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "mbio_StockIssuedDuringPeriodSharesEquityFeeOnAtMarketOffering": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Shares issued equity fee on the market offering.", "label": "Stock Issued During Period Shares ,Equity Fee On At The Market Offering", "verboseLabel": "Issuance of common shares - Equity fee on At-the-Market Offering (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEquityFeeOnAtMarketOffering", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "mbio_StockIssuedDuringPeriodSharesNewIssuesEquityFeeOnPublicOffering": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues, Equity fee on Public Offering", "verboseLabel": "Issuance of common shares - Equity fee on Public Offering (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssuesEquityFeeOnPublicOffering", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "mbio_StockIssuedDuringPeriodValueAtMarketingOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued at the market offering", "label": "Stock Issued During Period Value, At The Marketing Offering", "verboseLabel": "Issuance of common shares, net of offering costs - At-the-Market Offering" } } }, "localname": "StockIssuedDuringPeriodValueAtMarketingOffering", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "mbio_StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of number of shares issued at equity market offering.", "label": "Issuance of common shares - Equity fee on At-the-Market Offering", "verboseLabel": "Issuance of common shares - Equity fee on At-the-Market Offering" } } }, "localname": "StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "mbio_StockIssuedDuringPeriodValueIssuedForFoundersAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period Value Issued For Founders Agreement", "terseLabel": "Issuance of common shares - Founders Agreement" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForFoundersAgreement", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "mbio_StockIssuedDuringPeriodValueNewIssuesEquityFeeOnPublicOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity fee paid for new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues, Equity fee on Public Offering", "verboseLabel": "Issuance of common shares - Equity fee on Public Offering" } } }, "localname": "StockIssuedDuringPeriodValueNewIssuesEquityFeeOnPublicOffering", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "mbio_SummaryOfWarrantActivitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of warrant activities [Table Text Block]", "label": "Summary of warrant activities [Table Text Block]", "terseLabel": "Summary of Warrant Activities" } } }, "localname": "SummaryOfWarrantActivitiesTableTextBlock", "nsuri": "http://www.mustangbio.com/20210630", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r34", "r64" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r132", "r133", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r224", "r226" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r109", "r128", "r129", "r198", "r223", "r225" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r109", "r128", "r129", "r198", "r223", "r225" ], "lang": { "en-us": { "role": { "label": "Products And Services [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r130", "r132", "r133", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r224", "r226" ], "lang": { "en-us": { "role": { "label": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r130", "r132", "r133", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r224", "r226" ], "lang": { "en-us": { "role": { "label": "Range [Member]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Repurchase Agreement Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.mustangbio.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "totalLabel": "Total accounts payable and accrued expenses", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails", "http://www.mustangbio.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accounts Payable and Accrued Expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r24" ], "calculation": { "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r22", "r116" ], "calculation": { "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r13" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "verboseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r67", "r68", "r69", "r156", "r157", "r158" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r41", "r50", "r180" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Accretion of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potentially dilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements And Nonarrangement Transactions [Member]", "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsTables" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r62", "r101", "r103", "r107", "r111", "r167", "r169", "r172", "r212", "r216" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r3", "r4", "r33", "r62", "r111", "r167", "r169", "r172" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "verboseLabel": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r136", "r155" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlansNarrativeDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsAwardsDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityTables" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r55", "r56", "r57" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Fixed assets (acquired but not paid)" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r20", "r52" ], "calculation": { "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.mustangbio.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails", "http://www.mustangbio.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r6", "r53", "r59", "r211" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r46", "r52", "r58" ], "calculation": { "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of the period", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of the period", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails", "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r46", "r173" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "verboseLabel": "Supplemental disclosure of noncash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r60", "r62", "r79", "r80", "r81", "r83", "r85", "r91", "r92", "r93", "r111", "r172" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class Of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails", "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation", "http://www.mustangbio.com/role/StatementCondensedBalanceSheets", "http://www.mustangbio.com/role/StatementCondensedBalanceSheetsParenthetical", "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrant exercise price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "periodEndLabel": "Warrants outstanding, ending", "periodStartLabel": "Warrants outstanding, beginning" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r126", "r134" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r163", "r164", "r166" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "License, Clinical Trial and Sponsored Research Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r29", "r120", "r214", "r221" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies.", "verboseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Class A Common Shares [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails", "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation", "http://www.mustangbio.com/role/StatementCondensedBalanceSheets", "http://www.mustangbio.com/role/StatementCondensedBalanceSheetsParenthetical", "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares available for future sale" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlansNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails", "http://www.mustangbio.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails", "http://www.mustangbio.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails", "http://www.mustangbio.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r12", "r123" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesSubscribedButUnissued": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.", "label": "Common Stock, Shares Subscribed but Unissued", "terseLabel": "Common stock, shares issuable" } } }, "localname": "CommonStockSharesSubscribedButUnissued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails", "http://www.mustangbio.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesSubscriptions": { "auth_ref": [ "r12", "r122" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.", "label": "Common Stock, Value, Subscriptions", "netLabel": "Aggregate value of shares subscribed", "terseLabel": "Common stock issuable, 52,019 and 2,103,122 shares as of June 30, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockSharesSubscriptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails", "http://www.mustangbio.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r12" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common Stock ($0.0001 par value), 150,000,000 and 125,000,000 shares authorized as of June 30, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction In Progress [Member]", "terseLabel": "Construction in Process [Member]" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r50", "r114" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentNarrativeDetails", "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r136", "r155" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]", "terseLabel": "Schedule of Stock-Based Compensation Expense" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r24", "r65", "r186" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Payables and accrued expenses - related party" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss per Share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "verboseLabel": "Net loss per common share outstanding, basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r86", "r87", "r88", "r89" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r154" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options", "terseLabel": "Unrecognized share-based compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsAwardsDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized compensation recognition period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsAwardsDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r153" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock Options [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlansNarrativeDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r67", "r68", "r69", "r71", "r76", "r78", "r90", "r112", "r123", "r125", "r156", "r157", "r158", "r161", "r162", "r174", "r175", "r176", "r177", "r178", "r179", "r227", "r228", "r229" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails", "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture And Fixtures [Member]", "terseLabel": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r39" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense.", "verboseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General And Administrative Expense [Member]", "terseLabel": "General and Administrative [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED STATEMENTS OF OPERATIONS" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "auth_ref": [ "r49" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Due to Related Parties", "verboseLabel": "Payable and accrued expenses - related party" } } }, "localname": "IncreaseDecreaseInDueToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "auth_ref": [ "r49" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in receivables classified as other.", "label": "Increase (Decrease) in Other Receivables", "negatedLabel": "Other receivables - related party" } } }, "localname": "IncreaseDecreaseInOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r49" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expenses, Other", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r41", "r121" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest Income, Other", "verboseLabel": "Interest income" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r45", "r47", "r54" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "verboseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r27", "r62", "r104", "r111", "r168", "r169", "r170", "r172" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r17", "r62", "r111", "r172", "r213", "r219" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r28", "r62", "r111", "r168", "r169", "r170", "r172" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "verboseLabel": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery And Equipment [Member]", "terseLabel": "Machinery and Equipment [Member]" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r46" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "Cash Flows from Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r46" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Cash Flows from Investing Activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r46", "r48", "r51" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Cash Flows from Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r35", "r36", "r37", "r51", "r62", "r70", "r72", "r73", "r74", "r75", "r77", "r78", "r82", "r101", "r102", "r105", "r106", "r108", "r111", "r172", "r215", "r222" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.mustangbio.com/role/StatementCondensedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net Loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows", "http://www.mustangbio.com/role/StatementCondensedStatementsOfOperations", "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r40" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "verboseLabel": "Other income (expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "verboseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r101", "r102", "r105", "r106", "r108" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r182" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities - short-term" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r182" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities - long-term" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r181" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use asset, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Description of Business and Liquidity and Capital Resources" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r1", "r171" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "verboseLabel": "Organization, Description of Business and Liquidity and Capital Resources" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureOrganizationDescriptionOfBusinessAndLiquidityAndCapitalResources" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccountsPayableAndAccruedLiabilities": { "auth_ref": [], "calculation": { "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.", "label": "Other Accounts Payable and Accrued Liabilities", "terseLabel": "Other" } } }, "localname": "OtherAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r23" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "verboseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivables": { "auth_ref": [ "r32" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from parties in nontrade transactions, classified as other.", "label": "Other Receivables", "verboseLabel": "Other receivables - related party" } } }, "localname": "OtherReceivables", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Expenses" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r44" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedLabel": "Offering costs for the issuance of common shares - Public Offering", "verboseLabel": "Aggregate fees of stock issuance" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails", "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r42" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedLabel": "Purchase of research and development licenses" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r42" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of fixed assets" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable preferred class A stock or outstanding convertible preferred class A stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Preferred Class A [Member]", "terseLabel": "Preferred Class A [Member]" } } }, "localname": "PreferredClassAMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails", "http://www.mustangbio.com/role/StatementCondensedBalanceSheets", "http://www.mustangbio.com/role/StatementCondensedBalanceSheetsParenthetical", "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails", "http://www.mustangbio.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails", "http://www.mustangbio.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r11" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock ($0.0001 par value), 2,000,000 shares authorized, 250,000 shares of Class A preferred stock issued and outstanding as of June 30, 2021 and December 31, 2020, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r3", "r18", "r19" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "verboseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r43" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common shares", "verboseLabel": "Proceeds from issuance of common shares - Public Offering" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails", "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r43" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from issuance of common shares under ESPP" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r22", "r117" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r119", "r233", "r234", "r235" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosurePropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r21", "r115" ], "calculation": { "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r7", "r8", "r117", "r220" ], "calculation": { "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r7", "r117" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r7", "r115" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r131", "r185", "r186" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r185" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party", "terseLabel": "Expenses from related party transaction" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Agreements" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r131", "r185", "r188", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r183", "r184", "r186", "r189", "r190" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Agreements" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "License, Clinical Trial and Sponsored Research Agreements" } } }, "localname": "ResearchAndDevelopmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": { "auth_ref": [ "r113" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.", "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off", "terseLabel": "Research and development for licenses acquired", "verboseLabel": "Research and development - licenses acquired" } } }, "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails", "http://www.mustangbio.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r160" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "terseLabel": "Research and development", "verboseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails", "http://www.mustangbio.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and Development [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r58", "r211", "r217" ], "calculation": { "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "verboseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r5", "r9", "r58", "r232" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "verboseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock Awards [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsAwardsDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityTables" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units R S U [Member]", "terseLabel": "Restricted Stock Units [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsAwardsDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityTables" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r14", "r125", "r159", "r218", "r230", "r231" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureOrganizationDescriptionOfBusinessAndLiquidityAndCapitalResourcesDetails", "http://www.mustangbio.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r67", "r68", "r69", "r71", "r76", "r78", "r112", "r156", "r157", "r158", "r161", "r162", "r227", "r229" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accounts Payable and Accrued Expenses" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Potentially Dilutive Securities" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Research and Development Arrangement, Contract to Perform for Others [Table Text Block]", "terseLabel": "Schedule of License, Clinical Trial and Sponsored Research Agreements" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r22", "r117" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r63", "r187", "r188" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r6", "r58", "r211", "r217" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "verboseLabel": "Reconciliation of Cash, Cash Equivalents, and Restricted Cash" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r136", "r155" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlansNarrativeDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsAwardsDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r140", "r149", "r151" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Schedule of Summarizes Stock Option Activities" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedules of Restricted Stock and Restricted Stock Unit Activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r49" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Compensation", "verboseLabel": "Stock-based compensation expenses" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails", "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsAwardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsAwardsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r146" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsAwardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r146" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsAwardsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Nonvested, Number, Ending Balance", "periodStartLabel": "Nonvested, Number, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsAwardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Restricted stock and RSU rollforward" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsAwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Nonvested, Ending Balance", "periodStartLabel": "Nonvested, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsAwardsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsAwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsAwardsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsAwardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsAwardsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlansNarrativeDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsAwardsDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityTables" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Additional shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlansNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlansNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlansNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Options vested and exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, options vested and exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r142", "r155" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options, Outstanding, Number, Ending Balance", "periodStartLabel": "Stock Options, Outstanding, Number, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Options rollforward" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Ending", "periodStartLabel": "Weighted Average Exercise Price, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r134", "r139" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlansNarrativeDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockUnitsAwardsDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityTables" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlansNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Life, Options vested and exercisable (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Life, Options outstanding (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionActivitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "verboseLabel": "Shares issued, price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balances (in shares)", "periodStartLabel": "Balances (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r10", "r11", "r12", "r60", "r62", "r79", "r80", "r81", "r83", "r85", "r91", "r92", "r93", "r111", "r123", "r172" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails", "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation", "http://www.mustangbio.com/role/StatementCondensedBalanceSheets", "http://www.mustangbio.com/role/StatementCondensedBalanceSheetsParenthetical", "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r31", "r67", "r68", "r69", "r71", "r76", "r78", "r90", "r112", "r123", "r125", "r156", "r157", "r158", "r161", "r162", "r174", "r175", "r176", "r177", "r178", "r179", "r227", "r228", "r229" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails", "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails", "http://www.mustangbio.com/role/StatementCondensedBalanceSheets", "http://www.mustangbio.com/role/StatementCondensedBalanceSheetsParenthetical", "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r67", "r68", "r69", "r90", "r198" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails", "http://www.mustangbio.com/role/StatementCondensedBalanceSheets", "http://www.mustangbio.com/role/StatementCondensedBalanceSheetsParenthetical", "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r55", "r56", "r57" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "verboseLabel": "Issuance of common shares - Founders Agreement" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r11", "r12", "r123", "r125" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common shares under ESPP (in shares)", "verboseLabel": "Number of shares purchased under ESPP" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlansNarrativeDetails", "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Shares issued for services (in shares)", "verboseLabel": "Issuance of common shares - Founders Agreement (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails", "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r11", "r12", "r123", "r125" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common shares (in shares)", "verboseLabel": "Issuance of common shares, net of offering costs- Public Offering (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails", "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r11", "r12", "r123", "r125" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures", "verboseLabel": "Stock-based compensation expenses (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r11", "r12", "r123", "r125" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common shares under ESPP" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r11", "r12", "r123", "r125" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common shares, net of offering costs- Public Offering" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r11", "r12", "r125", "r135", "r150" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures", "verboseLabel": "Stock-based compensation expenses" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r12", "r15", "r16", "r62", "r110", "r111", "r172" ], "calculation": { "http://www.mustangbio.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balances", "periodStartLabel": "Balances", "totalLabel": "Total Stockholders' Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedBalanceSheets", "http://www.mustangbio.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "verboseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r61", "r125", "r127" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "verboseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails", "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r94", "r95", "r96", "r97", "r98", "r99", "r100" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesDetails", "http://www.mustangbio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "verboseLabel": "Weighted average number of common shares outstanding, basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.mustangbio.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r119": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r127": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r166": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r171": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r236": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r237": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r238": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r239": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r241": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r242": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r66": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r89": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" } }, "version": "2.1" }